Daxor Corporation (DXR)

Market Cap	59.79M +63.5%
Revenue (ttm)	26,688 -77.7%
Net Income	9.17M +1,609.7%
EPS	1.81 +1,567.3%
Shares Out	5.83M
PE Ratio	5.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158
Open	n/a
Previous Close	10.82
Day's Range	n/a
52-Week Range	7.57 - 14.76
Beta	0.29
Analysts	Buy
Price Target	22.50 (+119.3%)
Earnings Date	Feb 27, 2026

About DXR

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1970
• Employees: 45
• Stock Exchange: NASDAQ
• Ticker Symbol: DXR
• Website: https://www.daxor.com

Financial Performance

In 2025, Daxor's revenue was $26,688, a decrease of -77.71% compared to the previous year's $119,714. Earnings were $9.17 million, an increase of 1609.71%.

Analyst Summary

According to 2 analysts, the average rating for DXR stock is "Buy." The 12-month stock price target is $22.5, which is an increase of 119.30% from the latest price.

Price Target

$22.5

(119.30% upside)

Analyst Consensus: Buy